Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders by Sarah van Veen et al.
REVIEW ARTICLE
published: 27 May 2014
doi: 10.3389/fnmol.2014.00048
Cellular function and pathological role of ATP13A2 and
related P-type transport ATPases in Parkinson’s disease and
other neurological disorders
Sarah van Veen1†, Danny M. Sørensen1†, Tine Holemans1, Henrik W. Holen2, Michael G. Palmgren2
and Peter Vangheluwe1*
1 Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
2 Department of Plant and Environmental Sciences, Centre for Membrane Pumps in Cells and Disease – PUMPkin, University of Copenhagen, Frederiksberg,
Denmark
Edited by:
Jean-Marc Taymans, KU Leuven,
Belgium
Reviewed by:
Daniele Bottai, University of Milan,
Italy
Darren J. Moore, Swiss Federal
Institute of Technology, Lausanne
(EPFL), Switzerland
*Correspondence:
Peter Vangheluwe, Laboratory of
Cellular Transport Systems,
Department of Cellular and
Molecular Medicine, ON1, Campus
Gasthuisberg, KU Leuven,
Herestraat 49, Box 802, B3000
Leuven, Belgium
e-mail: peter.vangheluwe@
med.kuleuven.be
†These authors have contributed
equally to this work.
Mutations in ATP13A2 lead to Kufor-Rakeb syndrome, a parkinsonism with dementia.
ATP13A2 belongs to the P-type transport ATPases, a large family of primary active
transporters that exert vital cellular functions. However, the cellular function and
transported substrate of ATP13A2 remain unknown. To discuss the role of ATP13A2 in
neurodegeneration, we first provide a short description of the architecture and transport
mechanism of P-type transport ATPases. Then, we briefly highlight key P-type ATPases
involved in neuronal disorders such as the copper transporters ATP7A (Menkes disease),
ATP7B (Wilson disease), the Na+/K+-ATPases ATP1A2 (familial hemiplegic migraine) and
ATP1A3 (rapid-onset dystonia parkinsonism). Finally, we review the recent literature of
ATP13A2 and discuss ATP13A2’s putative cellular function in the light of what is known
concerning the functions of other, better-studied P-type ATPases. We critically review the
available data concerning the role of ATP13A2 in heavy metal transport and propose a
possible alternative hypothesis that ATP13A2 might be a flippase. As a flippase, ATP13A2
may transport an organic molecule, such as a lipid or a peptide, from one membrane
leaflet to the other. A flippase might control local lipid dynamics during vesicle formation
and membrane fusion events.
Keywords: alpha-synuclein, mitochondria, mitophagy, lysosome, dystonia, parkinsonism, flippase, heavy metal
toxicity
INTRODUCTION
Neurodegenerative diseases, the fourth leading cause of death in
developed countries, are characterized by progressive loss of neu-
rons within the central nervous system leading to motor and
cognitive dysfunction. Alzheimer’s disease (AD) and Parkinson’s
disease (PD) are the most common neurodegenerative disorders
(Lees et al., 2009; Tolleson and Fang, 2013). Their prevalence is
increasing as a consequence of the ageing population and lack
of successful treatments. PD is a progressive movement disorder
characterized by severe loss of dopaminergic neurons in the sub-
stantia nigra pars compacta (Lees et al., 2009). As a consequence
of cell death, dopamine content is reduced in the basal ganglia,
leading to themotor symptoms observed in patients. The cardinal
symptoms of PD are resting tremor, muscle rigidity (stiffness of
limbs), bradykinesia (slowness of movements) and postural insta-
bility (gait or balance problems) (reviewed in Jankovic, 2008; Lees
et al., 2009; Tolleson and Fang, 2013).
A second hallmark of PD is the accumulation of aggregated α-
synuclein into Lewy bodies (LBs) (Polymeropoulos et al., 1997).
Moreover, mutations in the SNCA (α-synuclein) gene were found
to be associated with the familial cases of early-onset Parkinson’s
disease (Spillantini et al., 1997). α-synuclein is able to form amy-
loid fibrils, β-sheet structures prone to aggregation, which is
its main pathogenic feature. α-synuclein overexpression results
in endoplasmic reticulum (ER) stress, vesicle trafficking defects,
impairment of the ubiquitin-proteasome system and mitochon-
drial dysfunction (reviewed in Auluck et al., 2010; Bendor et al.,
2013).
α-synuclein is mainly found at the presynaptic terminals of
neurons (Maroteaux et al., 1988). In presynaptic terminals, α-
synuclein interacts with the membranes of synaptic vesicles and
associated proteins, where it appears to be a critical regulator of
vesicle dynamics at the synapse (reviewed in Auluck et al., 2010;
Bendor et al., 2013). It acts as a trafficking partner of synapto-
brevin II (sybII) (Gordon and Cousin, 2014). At this location,
α-synuclein facilitates the entry of sybII into SNARE complexes,
which is a key step in the exocytotic fusion of synaptic vesicles
with the presynaptic terminal (Burre et al., 2010; Gordon and
Cousin, 2014). The acidic C-terminal of α-synuclein interacts
with sybII whereas its N-terminal membrane-associated region is
an inducible amphipathic α-helix that obtains its structure only
after contact with the membrane (Auluck et al., 2010; Bendor
et al., 2013). The amphipathic helix does not enter the membrane
bilayer, but aligns itself parallel to the bilayer axis. Amphipathic
α-helices are found in several proteins that regulate membrane
vesicle trafficking and it is becoming increasingly clear that they
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function as membrane curvature sensors (Drin et al., 2007; Drin
and Antonny, 2010; Jensen et al., 2011). Synucleins have been
shown to both induce and sense membrane curvature (Middleton
and Rhoades, 2010; Varkey et al., 2010; Pranke et al., 2011), which
can have a significant impact on the basal fusogenic properties of
synaptic vesicles.
α-synuclein aggregates accumulate in PD and are cleared via
various routes, mainly including the ubiquitin-proteasome sys-
tem, autophagy and lysosomal degradation pathways (Webb et al.,
2003; Cuervo et al., 2004). Besides the accumulation of misfolded
proteins, PD is further associated with mitochondrial dysfunc-
tion generating reactive oxygen species (ROS) and oxidative
stress (Ayala et al., 2007; Auluck et al., 2010). These phenom-
ena mutually affect each other as diseased mitochondria generate
more ROS, which in turn exacerbates protein folding defects.
Thus clearance of dysfunctional or damaged mitochondria and
proper functioning of the protein quality control are essential for
neuronal fitness and survival, but are impaired in PD (Devine
et al., 2011; Jin and Youle, 2012; Tofaris, 2012; Dehay et al.,
2012a). Protein quality control depends on both the proteasome
and lysosome. The lysosome mediates end-stage degradation
of obsolete or damaged cytoplasmic material, including pro-
tein aggregates and organelles such as mitochondria, through
autophagy pathways (Webb et al., 2003; Cuervo et al., 2004; Mak
et al., 2010; Jin and Youle, 2012; Tofaris, 2012; Dehay et al.,
2012a).
ATP13A2 is a late endosomal/lysosomal P5-type transport
ATPase that is emerging as a critical regulator of lysosomal func-
tions (Ramirez et al., 2006; Usenovic et al., 2012a; Dehay et al.,
2012b; Tsunemi and Krainc, 2014). Mutations in the ATP13A2
gene, belonging to the PARK9 PD susceptibility locus, lead to
the Kufor-Rakeb syndrome (KRS), a severe early-onset auto-
somal recessive form of PD with dementia (Ramirez et al.,
2006). Overexpression of ATP13A2 suppresses α-synuclein tox-
icity. This links two genetic risk factors of PD, i.e. ATP13A2
and α-synuclein, highlighting the central role of ATP13A2 in
PD (Gitler et al., 2009). Loss of ATP13A2 function is also asso-
ciated with neuronal ceroid lipofuscinosis, a lysosomal storage
disorder (Farias et al., 2011; Bras et al., 2012; Schultheis et al.,
2013).
This review will focus on ATP13A2 as an orphan member of
the family of P-type transport ATPases. P-type ATPases are a large
family of evolutionarily related primary transporters present in
Archaea, Bacteria and Eukarya (reviewed in Kuhlbrandt, 2004;
Palmgren and Nissen, 2011). They use the energy derived from
ATP hydrolysis to transport various substrates, ranging from ions
to lipids, across biological membranes against their concentration
gradients. P-type ATPases are crucial for the generation of elec-
trochemical gradients, which fuel vital cellular processes, such as
secondary transport, excitability, vesicular transport and osmotic
balance.
In the following sections we will give a short description
of the architecture and transport mechanism of classical P-
type transport ATPases. Then, we will provide an overview of
those P-type ATPases that are implicated in neuronal disor-
ders. Finally, we will review the recent literature of ATP13A2
and use available knowledge on P-type ATPase functions to
discuss ATP13A2’s putative cellular function and pathological
role in PD.
THE FAMILY OF P-type ATPases
GENERAL FEATURES OF P-type ATPases
P-type ATPases are biological pumps omnipresent in all forms of
life, which are recognized by several conserved signature motifs
associated with their catalytic mechanism (Axelsen and Palmgren,
1998). The main characteristic of all P-type ATPases is the for-
mation of an acid-stable aspartyl phosphate intermediate during
the catalytic cycle (hence the name P-type). The phosphorylated
Asp residue is located in a highly conserved DKTG sequencemotif
located in the cytoplasmic part of the proteins. The events of auto-
phosphorylation and auto-dephosphorylation are tightly coupled
to substrate binding, transport and release.
According to sequence comparison and phylogenetic analy-
sis, the P-type transport ATPase family can be classified into five
distinct subfamilies (P1–P5), which can be further divided into
additional subgroups (A, B, etc.) (Axelsen and Palmgren, 1998)
(reviewed in Kuhlbrandt, 2004; Palmgren and Nissen, 2011).
Importantly, the phylogenetic division correlates well with differ-
ences in the preferred transport substrates. The P1-P3 ATPases are
well-characterized ion pumps: the P1A are part of bacterial K+
transport systems, the P1B transport heavy metals, the P2A and
P2B are Ca2+ pumps, the P2C Na+/K+- and H+/K+-pumps are
found in animals, the P2D are Na+ pumps in fungi and mosses
and the plasma membrane H+ pumps of P3A are present in
fungi and plants. The P3B corresponds to a small group of bac-
terial Mg2+ transporters. In contrast to inorganic ion transport,
P4 ATPases participate in lipid flipping across membranes, gen-
erating membrane curvature and exposing or removing relevant
signaling lipids. The substrate specificity of the last subfamily, the
P5 ATPases, has yet to be revealed.
Based on the conserved P-type ATPase motifs, 36 human
genes are recognized and annotated in databases to encode for
P-type ATPases. These include 2 copper-ATPases, 4 Na+/K+-
ATPases, 2 H+/K+-ATPases, 9 Ca2+-ATPases, 14 putative lipid
flippases and 5 P5-type ATPases with unknown substrate speci-
ficity (ATP13A1-5). Figure 1 displays the phylogenetic relation-
ship of these 36 human P-type ATPases and their orthologs in
key animal model organisms. Many P-type ATPases display broad
expression profiles and fulfill many housekeeping functions, while
the expression of other P-type ATPases is restricted to specific
tissues e.g., brain, heart, skeletal muscle, etc.
P-type ATPases use metabolic energy (ATP) to actively pump
substrates against an electrochemical gradient. To prevent back-
flow of transported ligand(s), P-type ATPases use an alternating
access mechanism (Figure 2). After substrate binding from one
side, the access pathways from both sides of the membrane are
transiently closed, effectively occluding the transported ion(s)
in the membrane domain, before releasing them to the other
side of the membrane. In addition, the affinity toward the sub-
strate is different at both sides of the membrane. High affinity
binding occurs at the side of the membrane with low sub-
strate availability, whereas a drop in the affinity at the other
side of the membrane leads to spontaneous release. These two
features allow P-type ATPases to generate steep concentration
Frontiers in Molecular Neuroscience www.frontiersin.org May 2014 | Volume 7 | Article 48 | 2
van Veen et al. Cellular role of ATP13A2 in Parkinson’s disease
FIGURE 1 | Phyologenetic tree of the human P-type ATPases.
Phylogenetic tree based on the core protein sequences of 137 animal
homologues of the 36 human P-type ATPase isoforms. ATP13A2
homologues were obtained from the database Homologene http://www.
ncbi.nlm.nih.gov/homologene. Core protein sequences were generated
according to the methodology described in Axelsen and Palmgren
(1998). The 36 human P-type ATPases are indicated. Of note, only
animal isoforms are depicted, so the P3A-type ATPases, which are
uniquely found in fungi and plants and the small class of bacterial
Mg+-ATPases of the P3B group and bacterial pumps belonging to P1A
are not represented. The phylogenetic tree was rendered using www.
phylogeny.fr (Dereeper et al., 2008, 2010).
and charge gradients (Kuhlbrandt, 2004; Palmgren and Nissen,
2011).
The transport mechanism of P-type ATPases can be described
by the model of Post-Albers (Albers, 1967; reviewed in
Kuhlbrandt, 2004; Palmgren and Nissen, 2011). During each
catalytic cycle, the pumps oscillate between four major confor-
mations (Figure 2): E1, E1P, E2P, and E2. The E1 state displays
high-affinity ion-binding sites that are exposed to the cytosol.
Upon ion binding, the protein reacts with an ATP nucleotide cat-
alyzing auto-phosphorylation generating the E1P state in which
ions are occluded. Then, the protein undergoes an often rate lim-
iting transition to the E2P state where the transport binding sites
are transformed into low-affinity sites facing the extra-cytosolic
side of the membrane. This releases the ion(s) and allows the
binding of specific counterion(s). This binding triggers E2P auto-
dephosphorylation, returning to the E2 ground state in which
counter-ions are occluded. All P-type ATPases are inhibited by
orthovanadate, an inorganic phosphate mimic that locks the
enzyme in the E2P conformation. Finally, the transition to E1
allows release of counter-ions at the cytosolic side to re-initiate
the catalytical cycle.
The transport process can be overall electrogenic if transloca-
tion occurs of an unequal amount of charges at both sides of the
membrane. Examples are the Na+/K+-ATPase, which transports
two Na+ ions out of the cell in exchange for three K+ ions per
hydrolyzed ATP, and the SERCA Ca2+-ATPases, which transport
two Ca2+ ions from the cytoplasm to the lumen of the ER/SR
for two to three H+ in the other direction. Other P-type ATPases
transport only in one direction using either the forward E1 to
E1P step to bind the transported substrate (P1B copper-ATPase,
P3 H+-ATPase) while others use the E2P step for substrate bind-
ing (P4 lipid flippases) (Kuhlbrandt, 2004; Palmgren and Nissen,
2011).
THE P-type ATPase ARCHITECTURE
The two archetypical members of the P-type ATPase family are the
sarco(endo)plasmic reticulum (SR/ER) Ca2+-ATPase SERCA1a
and the (α1 subunit of) Na+/K+-ATPase for which there is a
wealth of structural and kinetic information. SERCA1a was the
first P-type ATPase to have its structure solved at high resolu-
tion (Toyoshima et al., 2000), providing detailed insights into the
overall domain organization of a P-type ATPase. Since then, sev-
eral other conformational states of SERCA1a have been resolved
using several inhibitors, transition analogs and nucleotides lock-
ing the protein in intermediate steps of the transport mechanism.
Together with a strong biochemical characterization and extensive
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FIGURE 2 | General Post-Albers reaction scheme for P-type ATPases. A
cytosolic ligand (yellow, transported ligand 1) is transported to the
extracytosolic space, whereas an extracytosolic ligand (red,
counter-transported ligand 2) is imported into the cytosol. Note that the
number of ligands in each direction may vary between different P-type
ATPase isoforms. In short, P-type ATPases switch between two major
conformations E1, with ligand binding sites facing the cytosol, and E2, with
ligand binding sites facing the extracytosolic side of the membrane. The
induced fit of ligand 1 binding in E1 promotes phosphorylation by Mg+-ATP.
In this E1∼P state the ligand 1 becomes occluded. The rate-limiting E1∼P
to E2-P transition is accompanied by major conformational changes,
reorienting the ligand-binding sites toward the extracytosolic space. This
decreases the affinity of the binding site for ligand 1, whereas the affinity
for ligand 2 is increased. As a result, ligand 1 is released into the
extracytosolic space via an open exit pathway for ligand 1 and the
counter-transported ligand 2 can enter the binding cavity. The resulting
conformational changes lead to dephosphorylation of E2P and the released
inorganic phosphate is expelled. The ligand 2 becomes occluded,
whereupon the pump is reset to the E1 state, reducing the affinity for
ligand 2. The pump can now start a new cycle.
mutagenesis, this has culminated in a detailed description of the
transport mechanism of the Ca2+-ATPase at atomic resolution,
which provides the scaffold to understand the transport process
in other P-type ATPases. For a careful discussion of this topic,
the reader is referred to excellent in depth reviews and references
in (Toyoshima, 2009; Moller et al., 2010; Palmgren and Nissen,
2011).
Crystal structures have also been presented for other P-
type ATPases including the H+-ATPase of plants (Pedersen
et al., 2007), the Na+/K+-ATPase (Morth et al., 2007; Shinoda
et al., 2009; Kanai et al., 2013; Nyblom et al., 2013) and the
copper-ATPase of Legionella pneumophila (Gourdon et al., 2011)
(Figure 3). Comparison of these structures has revealed that
P-type ATPases share a strikingly similar fold despite strong
sequence divergence. Four principal domains are recognized,
which are conserved throughout the family: three cytoplasmic
domains (nucleotide-binding, N; phosphorylation, P; actuator,
A) and a transmembrane (TM) domain (M domain) (Figure 3).
During the catalytic transport process the N-domain binds ATP
and serves as a built-in protein kinase, which auto-phosphorylates
the P-domain. The A-domain acts as an intrinsic protein phos-
phatase dephosphorylating the P-domain later in the catalytic
cycle. The process of phosphorylation and dephosphorylation is
tightly coupled to formation and deformation of high-affinity
transport-binding sites in theM domain by an allosteric mecha-
nism (Toyoshima, 2009; Moller et al., 2010; Palmgren and Nissen,
2011).
The N-domain is the least conserved cytoplasmic domain
among P-type ATPases and forms the ATP binding pocket. It
is situated as a large insert into the P-domain sequence stretch
and is connected by a highly flexible hinge region linking the
N- and P-domains (Toyoshima et al., 2000). The strongly con-
served P-domain contains the P-type ATPase fingerprint with
the critical Asp residue (DKTG). During each catalytic cycle,
the Asp residue is alternately phosphorylated and dephosphory-
lated by the N-domain and the A-domain, respectively. A Lys in
the nucleotide interaction site of the N-domain (KGAPE) inter-
acts with the adenine ring of ATP delivering the γ-phosphate
to the active-site residue of the P-domain. This reaction renders
a high-energy aspartyl phosphate intermediate. Subsequently,
the A-domain subjects the bond to hydrolysis, catalyzed by
the Glu residue in the highly conserved signature motif TGE
(Toyoshima, 2009; Moller et al., 2010; Palmgren and Nissen,
2011).
The M-domain, the largest of the four principal domains,
comprises six to twelve α-helices (Bublitz et al., 2011) and plays
a crucial role in substrate binding and transport. The cytoplasmic
domains are connected to the M-domain by five flexible linker
regions, four in P1-type ATPases (Palmgren and Nissen, 2011).
The substrate translocation pathways are centered on the M1–M6
segments. M4 is critically important for substrate specificity and
coordinating the substrate in the binding pocket. The sequence
of the M4 region thus diverges between the five P-type subfami-
lies, corresponding to the difference in substrate specificities. M4
involves a highly conserved Pro residue, which induces unwind-
ing of M4. This twist exposes backbone carbonyl oxygens that are
used to coordinate the transported ligand (Palmgren and Nissen,
2011).
P-type ATPases also hold extended N- or C-terminal tails
that regulate pump activity by intra-molecular interaction
(Vandecaetsbeek et al., 2009) or via interaction of regulatory pro-
teins (Vincenzi et al., 1980). The extensions may in addition
control subcellular localization (Petris et al., 1998) or substrate
delivery (Gourdon et al., 2011). Often, the N and C termini are
auto-inhibitory, preventing the activation of the transporter and
requiring additional stimuli for pump activation (Ekberg et al.,
2010; Zhou et al., 2013).
THE P-type ATPase ION TRANSPORT CYCLE
To translocate substrates across the membrane, P-type pumps
undergo extensive conformational changes, which are driven by
ATP hydrolysis. In the next section, the general catalytic mech-
anism of P-type ATPases will be explained based on the Ca2+
transport cycle of the SERCA1a pump (based on references in
Toyoshima, 2009; Moller et al., 2010; Palmgren and Nissen, 2011).
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FIGURE 3 | Topology and architecture of the catalytic subunits of P-type
ATPases. (A) Planar topology models of the five classes of P-type ATPases
(P1-P5). Nucleotide-binding domains (N, yellow), actuator domains (A, green)
and phosphorylation domains (P, red) are indicated. The 6 TM helices
(Polymeropoulos et al., 1997; Spillantini et al., 1997; Jankovic, 2008; Lees
et al., 2009; Auluck et al., 2010; Tolleson and Fang, 2013) form the core
segment of the membrane (M) domain of all P-type ATPases, which is
depicted in dark blue, whereas additional N- and C-terminal helices are shown
in light blue. Of note, there is one exception for the P2 ATPases, a splice
variant of ATP2A2, SERCA2b, harbors an 11th TM helix at the C-terminus (not
shown, Vandecaetsbeek et al., 2009). (B) Resolved P-type ATPase crystal
structures, known up until now. The Legionella pneumophila CopA
copper-ATPase (PDB 3RFU), a P1B-type ATPase; the rabbit P2A-type ATPase
ATP2A1 (SERCA1a, PDB 2AGV), the Squalus acanthias Na+/K+-ATPase
α-subunit ATN1 (PDB 3A3Y), a member of the P2C group and the Arabidopsis
thaliana proton pump AHA2 (PBD 3B8C) of the P3-type ATPases. N-, A-, P-
and M-domains are indicated with similar colors as in the planar models.
Note that the obligatory subunits of the P1A, P2C and P4 are not shown.
Ca2+ entry and binding: E2→ E1 · 2Ca 2+
At the start of the catalytic cycle, cytosolic Ca2+ ions interact with
the high-affinity binding sites in the M-domain in the E1 con-
formation. The binding of the two Ca2+ ions is sequential and
cooperative. The first Ca2+ proceeds to site I where its binding
repositions a critical Asp residue onM6 (D800), which now forms
the second Ca2+ binding site II. Upon binding of the second
Ca2+, the gating residue E309 onM4will capture the second Ca2+
ion in site II.
Phosphorylation and occlusion: E1 · 2Ca 2+ → E1∼ P · 2Ca 2+
Via the induced fit mechanism of Ca2+ binding, the rearrange-
ment of the TM helices is transmitted to the P-domain creating
a Mg2+-binding site near the critical Asp residue (Asp351 in
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SERCA1a). Presence ofMg2+ is essential as this cofactor decreases
the electrostatic repulsion of the γ-phosphate of ATP by the
negatively charged Asp and hence, allows phosphate transfer. In
this way, ATPase activity of P-type transporters in the cytosolic
domains is tightly coupled to the ion binding in the M-domain,
preventing unnecessary ATP hydrolysis. The transition toward the
intermediate E1∼P phosphorylated state bends the P-domain and
tilts the A-domain that rests on the P-domain. This exerts strain
on the linkers between the A-domain and M1, M2, and M3 of
the M-domain. As a result, M1-M2 is partially lifted out of the
membrane forcing E309 in a fixed position, which closes the Ca2+
entry path (occlusion).
Ca2+ release: E1∼ P→ E2-P
Following complete γ-phosphate transfer, the ATP-mediated con-
nection between the N- and P-domains is lost. As a consequence,
the pump relaxes and the N-domain moves away from the cat-
alytic site and stretches the linker region between the M3 helix
and the A-domain. The generated tension triggers rotation of the
A-domain and results in transition to the low-energy E2P state.
The significant conformational changes associated with the E1P
to E2P transition is the rate-limiting step in the catalytical cycle.
The rearrangement of the pump opens the luminal exit path-
way for Ca2+ by spreading out M1/M2 and M3/M4 away from
M5/M6. In addition, this reduces the affinity of the Ca2+-binding
sites promoting the luminal release of Ca2+. In exchange, two to
three H+ ions bind with high affinity to the E2P state leading
to occlusion of the luminal gate and further rotation of the A-
domain. The A-domain rotation also brings the TGE loop closer
to the phosphorylation site, shielding the aspartyl-phosphate by
restricting the access of ADP or water.
Dephosphorylation and occlusion: E2-P → E2
The Ca2+-ATPase pump is reset to E1 by a series of reversal
reactions leading to E2P dephosphorylation and proton counter-
transport. Entry of a water molecule induces a new rotation of
the A-domain, which now precisely positions the Glu of the TGE-
loop and the water molecule to catalyze an attack on the aspartyl
phosphate. The rotation of the A-domain also repositionsM1/M2
and the cation-binding site with the protons becomes occluded.
Thereafter, the A-domain disengages from the phosphorylation
site resulting in transition of the E2 state to the relaxed E1
conformation associated with release of the counterions.
DOMAIN ORGANIZATION AND SIGNATURE MOTIFS IN P5B-type
ATPases
In comparison with the well-studied SERCA1a Ca2+ pump, little
is known about the P5-type ATPases to which ATP13A2 belongs.
P5-type ATPases are found in all eukaryotic genomes, but are
absent in bacterial genomes (Moller et al., 2008; Sorensen et al.,
2010). Based on the conservation of residues in the putative
transport binding sites (Moller et al., 2008) and on their pre-
dicted TM topology (Sorensen et al., 2010), the P5 subfamily
can be divided into two groups, P5A and P5B (Figures 1, 3).
Exactly one P5A (ATP13A1 in humans) and at least one P5B iso-
form is found in all eukaryotic genomes, except for land plants,
which have lost the P5B genes (Moller et al., 2008). Multiple P5B
isoforms exist in higher vertebrates (four in humans, ATP13A2-5)
and some invertebrate lineages (three in Caenorhabditis elegans,
CATP-5 to 7).
The P5-ATPase membrane topology is unusual (Sorensen
et al., 2010). In addition to the 10 classical TM helices, two extra
TM spanning helices are predicted in the N terminus of the P5A
ATPases (Ma and Mb), whereas the P5B group is marked by a
single predicted N-terminal TM helix (Ma). Therefore, the P5A
would consist of 12 and the P5B of 11 TM helices. The poor
sequence conservation of the extra N-terminal helices suggest
that they are not critical for substrate coordination during trans-
port (Sorensen et al., 2010). Instead, as in other P-type ATPases,
the N-terminal region may directly function as a regulator of
catalytic function or serve as the docking site for other regula-
tory proteins (Gourdon et al., 2011). Of all P-type ATPases, only
the P5 and the P1B heavy metal pumps contain additional N-
terminal membrane-spanning segments (Figure 3). The structure
of a P1B pump, the CopA copper transporter, was recently solved
(Gourdon et al., 2011). The structure clearly depicts that the Mb
forms anN-terminal docking platform for the binding of a copper
chaperone, which delivers copper to the pump directly, or via the
N-terminal heavy metal binding domains (Gourdon et al., 2011).
Interestingly, also the P5 ATPases contain conserved Pro or Gly
residues at a similar position in the additional N-terminal mem-
brane helices (Mb for P5A ATPases Sorensen et al., 2010 and Ma
for P5B ATPases). In analogy herewith, the extended N terminus
of the P5 may follow a similar fold as in the P1B, representing a
docking platform for substrate delivery.
Like other P-type ATPases, P5 isoforms, including ATP13A2,
contain the key signature motifs KGAPE for ATP coordination
(N-domain), DKTG for auto-phosphorylation (P-domain) and
TGE for dephosphorylation (A-domain) (Kwasnicka-Crawford
et al., 2005; Ramirez et al., 2006). This indicates that P5-ATPases
like other P-type ATPases catalyze the hydrolysis of ATP to auto-
phosphorylate the enzyme on a conserved Asp residue in the
P-domain.
The presence of a highly conserved M4 region within P5
ATPases indicates that in P5-type ATPases the hydrolysis of ATP
may be coupled to the transport of a ligand close to the M4
region (Moller et al., 2008; Sorensen et al., 2010). Spontaneous
auto-phosphorylation has already been observed for the yeast
P5A ATPase Spf1p and the plant P5A ATPase HvP5A1 (Corradi
et al., 2012; Sorensen et al., 2012), but so far it remains unclear
whether P5B-ATPases such as ATP13A2 also form a phospho-
intermediate.
The M4 segment of the P5-type ATPase corresponds to the
putative substrate binding site and contains a double Pro in
(PPxxP) (Moller et al., 2008; Sorensen et al., 2010). This may
exacerbate the twist of the M4 segment imposed by the initial
Pro, which might have a significant impact on the mechanism
of substrate coordination and transport. P5A sequences contain
a PP(E/D)xPx(E/D) motif, whereas P5B sequences are character-
ized by a PP(A/V)xP(A/V)x motif (Moller et al., 2008; Sorensen
et al., 2010) (Figure 4). The negative charges in the unwound
M4 helix of P5A compared to the corresponding hydrophobic
residues in P5B may suggest that both subgroups display different
substrate specificities (Moller et al., 2008; Sorensen et al., 2010).
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FIGURE 4 | Sequence comparison of the TM helices in P-type ATPases of
various subfamilies. The residues involved in Ca2+ binding in the two Ca2+
binding sites (site 1 and 2) in the SERCA1a Ca2+ pump (ATP2A1) are
distributed over four TM helices: M4, 5, 6 and 8. The colored residues are
part of the Ca2+ binding sites in ATP2A1 and numbers 1 and 2 refer to the
number of the Ca2+-binding site to which the residue contributes (x is
contributing to both site 1 and site 2). The sequence of the M4, M5, M6 and
M8 helices is compared with those of the P-type ATPases that are involved in
neurological disorders. Also the yeast P5 ATPases Spf1p and Ypk9p, the
Ca2+/Mn2+-ATPase SPCA as well as the proton pump AHA2 are included for
comparison. M4 shows the highest degree of conservation. Highlighted in
red are conserved residues as compared to the ATP2A1 Ca2+ binding site
sequence, whereas in yellow the non-conserved residues are indicated. For
each subfamily, a signature motif can be recognized in M4, which
corresponds well with the substrate specificity. The PPELP and PPALP
sequences of P5A- and P5B-type ATPases have little in common with other
P-type ATPase signature motifs, which might indicate that the transported
ligand is significantly different.
For this reason, we will focus only on the P5B ATPases in this
review.
P-type ATPases AND NEURODEGENERATION
P-type ATPases play important roles in the nervous system, rang-
ing from regulation of Ca2+ homeostasis, osmotic balance, elec-
trical excitability, uptake of trace elements to vesicular transport
processes. It is therefore not surprising to see that loss-of-function
mutations in many P-type ATPase isoforms are detrimental for
neuronal functions. In the following sections we will provide a
short overview of those P-type ATPases that according to genetic
information are implicated in neurological disorders (Table 1).
P1B-type ATPases IN NEUROLOGICAL DISORDERS
The P1B-type ATPase subfamily consists of the two copper-
transporting isoforms in human, ATP7A and ATP7B. ATP7A is
ubiquitously expressed in all tissues, including the brain, but
except the liver, regulating homeostatic maintenance of cell cop-
per levels. ATP7B is highly expressed in the liver. Mutations in
ATP7A are associated with Menkes disease (MD) (Chelly et al.,
1993; Mercer et al., 1993; Vulpe et al., 1993), while ATP7B muta-
tions cause Wilson’s disease (WD) (Bull et al., 1993) (reviewed in
Gupta and Lutsenko, 2009; Kaler, 2011; Telianidis et al., 2013).
ATP7A
Mutations in ATP7A are associated with MD, an X-linked reces-
sive disorder characterized by progressive neurodegeneration and
connective tissue dysfunction (Chelly et al., 1993; Mercer et al.,
1993; Vulpe et al., 1993). The clinical manifestations of MD
include severe seizures associated with cerebral atrophy, vascular
abnormalities, kinky hair structure, hypopigmentation, growth
retardation and death in early childhood. These features originate
from a generalized copper deficiency that triggers dysfunction
of several cuproenzymes (Kaler, 2011). ATP7A mutations also
underlie occipital horn syndrome (OHS), a milder disease with
moderate neurologic symptoms and prominent connective tis-
sue disturbances (Kaler, 2011). Recently, a novel ATP7A-related
disease phenotype was discovered, spinal muscular atrophy, dis-
tal, X-linked 3 (SMAX3), which is characterized by atrophy of the
lower limb muscles (Kennerson et al., 2010).
ATP7A is targeted to the trans-Golgi network from where it
supplies copper to the copper-dependent enzymes as they migrate
through the secretory pathway. Under conditions of elevated
copper, ATP7A relocalizes to the plasma membrane where it pro-
motes the efflux of copper from cells (Petris et al., 1998). To
date, over 500 disease-causing variations of ATP7A have been
reported, mostly substitutions and deletions (ATP7A database,
www.LOVD.nl/ATP7A) which lead to misfolding (Kim et al.,
2002), impaired copper-induced trafficking (Kim et al., 2003) or
reduced copper-ATPase activity (Paulsen et al., 2006).
ATP7B
WD is an autosomal recessive disorder caused by mutations
in ATP7B (Bull et al., 1993), a copper-ATPase which is mainly
expressed in liver and implicated in biliary copper excretion
(Telianidis et al., 2013). ATP7B dysfunction results in the toxic
buildup of copper in liver. Brain copper accumulation develops
secondary to liver disease and leads to degeneration of the basal
ganglia. As a consequence, WD patients present movement disor-
ders such as tremor, dystonia and parkinsonism (Machado et al.,
2006).
A number of single nucleotide polymorphisms in ATP7B are
associated with an increased risk of AD (Squitti et al., 2013).
Furthermore, it has been suggested that a single mutated ATP7B
allele may confer susceptibility for (late-onset) parkinsonism
(Sechi et al., 2007).
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Table 1 | P-type ATPases involved in neuronal disorders.
P-type Gene Substrate Disorder Ref.
P1B ATP7A Cu+ Menkes disease (MD)
Occipital horn syndrome (OHS)
Spinal muscular atrophy, distal, X-linked 3 (SMAX3)
[OMIM:309400]
[OMIM:304150]
[OMIM:300489]
P1B ATP7B Cu+ Wilson disease (WD)
Possible genetic risk factor for Alzheimer’s disease (AD) and
parkinsonism
[OMIM:277900]
Bull et al., 1993; Telianidis
et al., 2013
P2B ATP2B3 Ca2+ Early onset X-linked spinocerebellar ataxia 1 [OMIM:300014]
P2C ATP1A2 Na+/K+ Familial hemiplegic migraine type 2 (FHM2)
Alternating hemiplegia of childhood 1 (AHC1)
[OMIM:602481]
[OMIM:104290]
P2C ATP1A3 Na+/K+ Rapid-onset dystonia parkinsonism (DYT12, RDP)
Alternating hemiplegia of childhood 2 (AHC2)
[OMIM:128235]
[OMIM:614820]
P4 ATP8A2 PS Cerebellar ataxia, mental retardation and disequilibrium
syndrome 4 (CAMRQ4)
[OMIM:615268]
P4 ATP10A ? Angelman syndrome (AS) Blanco-Arias et al., 2009
P5B ATP13A2 ? Kufor-Rakeb syndrome (KRS)
Neuronal ceroid lipofuscinosis (NCL)
[OMIM:606693]
P5B ATP13A4 ? Specific language impairment (SLI)
autism spectrum disorders (ASD)
Gourdon et al., 2011;
Lohmann and Klein, 2013
Ugolino et al., 2011
OMIM entries are shown for the most well established genetic disorders. References are shown for disorders that have been linked genetically to mutations in the
indicated gene(s).
P2-type ATPases IN NEUROLOGICAL DISORDERS
The P2-type ATPases constitute the best characterized subfamily
of P-type ATPases. The human P2 isoforms can be subdi-
vided into three groups, P2A, P2B and P2C (P2D is not rep-
resented in humans, but consists of eukaryotic Na+-ATPases).
The P2A group contains the well-known SERCA and Secretory
Pathway/Golgi (SPCA) Ca2+-ATPases, whereas the plasma mem-
brane Ca2+-ATPases (PMCAs) belong to the P2B-ATPases. The
P2C-subgroup encompasses the Na+/K+-ATPases and the gastric
H+/K+-pumps (Kuhlbrandt, 2004; Palmgren and Nissen, 2011).
Na+/K+-ATPase
The Na+/K+-ATPase generates vital Na+ and K+ gradients over
the plasma membrane by expelling three Na+ ions in exchange
for two K+ ions. This is essential for many physiological func-
tions in the nervous system such as cell volume control, the drive
of secondary active transport systems and the support of elec-
trical excitability (reviewed in Benarroch, 2011). The α-subunit
is the catalytical subunit of the Na+/K+-ATPase that exists in
four isoforms (ATP1A1-4 or α1-4), which display tissue specific
and developmental dependent expression. Only the ATP1A1-3
genes are expressed in the nervous system. The α-subunit forms a
hetero-oligomer with a β- and γ-subunit. β is critical for proper
targeting and affects the K+ affinity (Hasler et al., 2001), whereas
γ (belonging to the FXYD family) mainly regulates the Na+
affinity of the pump (Geering, 2005).
The neurological disorders familial hemiplegic migraine type 2
(FHM2), alternating hemiplegia of childhood (AHC), and rapid-
onset dystonia parkinsonism (RDP) are autosomal dominant
disorders caused by mutations of the Na+/K+-ATPase α2 (FHM2
and AHC1) and α3 (AHC2 and RDP) isoforms. α2 (ATP1A2) is
primarily expressed in astrocytes and drives Na+-dependent Glu
uptake and removes excess K+ from the extracellular space dur-
ing neuronal excitation. α3 (ATP1A3) is predominantly expressed
in neurons and is involved in post-stimulus recovery (reviewed in
Brashear et al., 2014).
ATP1A2. ATP1A2 mutations lead to FHM2, a severe subtype of
migraine with aura and temporary hemiparesis. More than 20
mutations in the α2-subunit are known to cause FHM2 (De Fusco
et al., 2003; Jurkat-Rott et al., 2004; Schack et al., 2012). A dis-
turbed clearance of extracellular K+ by glial cells underlies FHM2,
which is related to an impaired pumping rate (Schack et al.,
2012). ATP1A2 mutations may also underlie basilar migraine
(BM), which is a subtype of migraine with aura originating from
the brainstem or involvement of both hemispheres (Ambrosini
et al., 2005). In addition, a mutation in the ATP1A2 gene was also
identified in affected members of a family with AHC1 (Swoboda
et al., 2004). FHM2, BM, and AHC1 are allelic disorders with
overlapping phenotypes.
ATP1A3. Mutations in ATP1A3 (also known as dystonia-12,
DYT12) lead to RDP, which is a rare autosomal dominant move-
ment disorder with variable penetrance, characterized by the
abrupt start of dystonia with signs of parkinsonism (de Carvalho
Aguiar et al., 2004). The onset of RDP (at the age of 4–55) is
often triggered by physical or emotional stress, fever, childbirth,
or alcohol consumption. RDP-associated mutations are predom-
inantly located in highly conserved residues in the TM domain
of ATP1A3, which mainly affect the Na+ affinity (Rodacker et al.,
2006; Blanco-Arias et al., 2009). The resulting intracellular Na+
increase may possibly affect the Na+/Ca2+ exchange system and
subsequently lead to increased intracellular Ca2+ impacting on
Ca2+-dependent signaling pathways, such as neurotransmitter
Frontiers in Molecular Neuroscience www.frontiersin.org May 2014 | Volume 7 | Article 48 | 8
van Veen et al. Cellular role of ATP13A2 in Parkinson’s disease
release (Rodacker et al., 2006). Mutations in ATP1A3 are also
implicated in AHC2 (Heinzen et al., 2012), which generally has
earlier onset than RDP and is characterized by transient episodes
of hemiplegia often shifting from one side of the body to the other.
AHC2 and RDP present overlapping clinical features such as dys-
tonia with a bulbar preference (Heinzen et al., 2012; Brashear
et al., 2014).
According to the crystal structure of Na+/K+-ATPase, the C-
terminal tail is inserted within a binding pocket between TM
helices (Morth et al., 2007). This tail controls Na+ and proton
binding at the third Na+ site. At least eight disease mutations
occur in this C-terminal ion pathway (Poulsen et al., 2010). Two
disease mutations have been reported in which the C terminus is
extended by one Tyr residue in a patient with RDP (Blanco-Arias
et al., 2009) and by a 28-residue long segment in a patient with
FHM2 (Jurkat-Rott et al., 2004).
ATP2B3
PMCA isoforms (ATP2B1-4) remove Ca2+ from the cytosol to
the extracellular environment. ATP2B3 mutations cause early
onset X-linked spinocerebellar ataxia-1, a disorder characterized
by degeneration of the cerebellum (Zanni et al., 2012). Clinical
manifestations include hypotonia at birth, dysarthria, gait ataxia
difficulty standing, slow eyemovements and delayedmotor devel-
opment. PMCA3 is highly expressed in the cerebellum, a critical
region for motor coordination (Zanni et al., 2012).
P4-type ATPases IN NEUROLOGICAL DISORDERS
The human genome encodes 14 P4-type ATPases, which are
putative lipid flippases involved in aminophospholipid transport
across membrane bilayers. P4-type ATPases are the first class of P-
type transporters that do not transport inorganic ions (reviewed
in Graham, 2004; Poulsen et al., 2008; van der Mark et al., 2013).
ATP8A2
The P4-type ATPase ATP8A2 is a phosphatidylserine (PS) translo-
case, which is localized to the plasma membrane and highly
expressed in retina and brain, particularly in the cerebellum. The
P4 lipid flippase ATP8A2 is involved in localization of PS to the
inner leaflet of the plasma membrane (Zhu et al., 2012). A mis-
sense mutation located in aM domain of ATP8A2 is associated
with cerebellar ataxia, mental retardation and dysequilibrium
syndrome (CAMRQ), an autosomal recessive disorder character-
ized by dysarthric speech and cerebellar atrophy with or without
quadrupedal gait (Onat et al., 2013). Mice carrying loss-of-
function mutations in the Atp8a2 gene develop axonal degener-
ation resulting in progressive ataxia and neurodegeneration (Zhu
et al., 2012). Loss of ATP8A2 disrupts PS asymmetry which might
lead to fragile neuronal membranes that are more prone to degen-
eration. Defective vesicular trafficking may provide an alternative
explanation (Zhu et al., 2012).
ATP10A
ATP10A is a putative aminophospholipid translocase. ATP10A
maps within the most common interval of deletion (15q11-q13)
leading to Angelman syndrome (AS). This syndrome is marked
by neurobehavioral anomalies that include severe mental retarda-
tion, ataxia and epilepsy. AS patients with imprinting mutations
or with maternal deletions of 15q11-q13 display little or no
ATP10A expression (Meguro et al., 2001).
P5-type ATPases IN NEUROLOGICAL DISORDERS
Twomembers of the P5-type ATPases are implicated in neurolog-
ical disorders. Little is known about the substrate specificity and
cellular function of P5-type ATPases, but their putative function
is extensively discussed in section 5 of this review.
ATP13A2
Loss-of-function mutations in ATP13A2 (PARK9) are a known
cause of Kufor-Rakeb syndrome (KRS), an autosomal recessive
disorder characterized by juvenile-onset Parkinsonism associated
with dementia (Ramirez et al., 2006). This syndrome was first
described in 1994 in a consanguineous family originating from
Kufor-Rakeb, Jordan (Najim al-Din et al., 1994). Today, sev-
eral homozygous and compound heterozygous mutations have
been described that result in truncation of the ATP13A2 pro-
tein leading to loss-of-function (Ramirez et al., 2006; Schneider
et al., 2010; Crosiers et al., 2011; Park et al., 2011). The clinical
phenotype of KRS comprises pyramidal degeneration, supranu-
clear gaze palsy and severe cognitive decline (Williams et al.,
2005). Brain MRI of KRS patients revealed generalized atro-
phy and putaminal and caudate iron accumulation, classifying
KRS amongst neurodegeneration with brain iron accumulation
(Bruggemann et al., 2010; Schneider et al., 2010), although others
reported KRS patients without iron accumulation (Chien et al.,
2011). KRS can be classified as a complex dystonia, i.e., a form
of dystonia that occurs in conjunction with other neurological or
non-neurological symptoms (Lohmann and Klein, 2013; Klein,
2014).
Whereas wild-type ATP13A2 is localized to late endosomal
and lysosomal membranes (Ramirez et al., 2006), the truncat-
ing KRS mutations lead to retention of the protein in the ER
resulting in ER stress and proteasomal degradation via the ER-
associated degradation pathway (Ugolino et al., 2011). Other
missense mutations in ATP13A2 have been identified that are
associated with early-onset Parkinsonism (Di Fonzo et al., 2007;
Lin et al., 2008; Ning et al., 2008; Santoro et al., 2011). Similar to
KRS mutations, homozygous missense mutations disrupt normal
localization and function of ATP13A2 while heterozygous mis-
sense mutations may impair ATPase activity (Podhajska et al.,
2012). Moreover, ATP13A2 protein levels are increased in surviv-
ing neurons of humans with PD/dementia with LBs indicative of
a putative protective function of high levels of ATP13A2. In LBs
positive neurons ATP13A2 did not co-localize directly, but rather
surrounds the LBs (Ramonet et al., 2012).
In dogs (Farias et al., 2011; Wohlke et al., 2011) and mice
(Schultheis et al., 2013), loss of ATP13A2 elicits neuronal ceroid
lipofuscinosis (NCL), a lysosomal storage disorder characterized
by the accumulation of autofluorescent lipopigment. The phe-
notype of NCL partially overlaps with that of KRS and involves
dysarthria, cerebellar ataxia, rigidity, bradykinesia and cognitive
impairment. Atp13a2 deficient mice exhibit age-dependent sen-
sorimotor deficits that resemble motor symptoms observed in
KRS, NCL and PD patients. Moreover, loss of Atp13a2 leads
to lipofuscin accumulation and α-synuclein aggregation in the
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hippocampus, critical features of NCL and PD, respectively
(Schultheis et al., 2013). Also a homozygous ATP13A2 mis-
sense mutation was reported that is associated with juvenile
NCL in humans (Bras et al., 2012). Extensive lipofuscinosis was
demonstrated in neuronal and glial cells of cortex, basal gan-
glia and cerebellum (Bras et al., 2012). These findings underline
the importance of ATP13A2 in the lysosomal pathway for α-
synuclein degradation and suggest that lysosomal dysfunction
might represent a link between lipofuscinosis and α-synuclein
accumulation.
ATP13A4
ATP13A4 has been linked to language delay (Kwasnicka-Crawford
et al., 2005; Worthey et al., 2013) and autism spectrum disorders
(ASD) (Vallipuram et al., 2010). In two patients, disruption of
ATP13A4 led to specific language impairment characterized by
delayed expressive and receptive language, without further cogni-
tive deficiencies (Kwasnicka-Crawford et al., 2005). Moreover, in
a Finnish genome-wide screen for ASD, an autism susceptibility
locus was identified on chromosome 3q25-27, nearby ATP13A4
(Auranen et al., 2002). In six study participants, a Glu646Asp
sequence variant was found, which is located between the fourth
and fifth TM region of ATP13A4, near the conserved Asp residue
and the N-domain (Kwasnicka-Crawford et al., 2005).
There is very little knowledge concerning the biological role
of ATP13A4. In mice, Atp13a4 is mainly expressed in stomach
and brain (Schultheis et al., 2004). Atp13a4 expression varies
throughout all regions of the adult mouse brain, with the high-
est relative expression in cerebellum. Atp13a4 expression is also
developmentally regulated, peaking at late neurogenesis, suggest-
ing a function in neuronal development (Vallipuram et al., 2010;
Weingarten et al., 2012). In humans, ATP13A4 mRNA has been
detected in multiple organs, with relatively low expression in the
brain, where expression was observed in the lateral inferior frontal
cortex (Broca’s area) and the temporoparietal cortex (Wernicke’s
area) (Kwasnicka-Crawford et al., 2005), areas of importance for
language output and input, respectively. ATP13A4 is observed in
the ER membrane and increases intracellular Ca2+ levels when
overexpressed in COS-7 cells (Vallipuram et al., 2010). The intra-
cellular Ca2+ increase is not observed in cells overexpressing the
Glu646Asp variant, implying that the substitution might impair
the ability of ATP13A4 to regulate Ca2+ transport (Vallipuram
et al., 2010).
CELLULAR FUNCTION OF P5B ATPases IN MODEL
ORGANISMS
A major bottleneck in unraveling the role of ATP13A2 in neu-
rological disorders is the fact that virtually nothing is known
concerning the molecular function and substrate specificity of the
P5B-type ATPases. In this section, we will discuss the cellular role
of ATP13A2 orthologs in different model organisms.
YPK9 IN THE YEAST SACCHAROMYCES CEREVISIAE
Ypk9p (yeast PARK9), is the single P5B-type ATPase in the yeast
Saccharomyces cerevisiae and resides in the vacuolar membrane,
the yeast equivalent of the mammalian lysosome (Gitler et al.,
2009). Studies in yeast show that Ypk9p is involved in protecting
cells against Mn2+ toxicity (Gitler et al., 2009) and, more broadly,
heavy metals (Schmidt et al., 2009; Chesi et al., 2012; Kong
et al., 2014), but the ion specificity might be strain dependent
(Schmidt et al., 2009). Little or no other phenotypes have been
reported. According to the S. cerevisiae genome database (http://
yeastgenome.org) 74 genes or gene products have been reported
as interactors of YPK9. Most interactions are genetic (72 in total)
highlighting genes that when deleted in the absence of YPK9
result in synthetic growth effects or phenotypic suppression or
enhancement (Figure 5). Supplemental Table 1 integrates data
on interactions from high- and low-throughput studies in yeast
available at BioGrid (http://thebiogrid.org). The interactors vary
both with respect to cellular location and predicted function.
Surprisingly, only a few of the interactors are located in the endo-
some and vacuolar systems (6 out of 74 interactors). The most
prevalent interactions participate in vesicular trafficking and pro-
tein sorting (12 out of 74 interactors) and transcriptional flux (11
out of 74) (Figure 5).
Only one gene, TATA-binding protein-associated factor-1,
TAF1, has so far been reported to be synthetic lethal in combina-
tion with deletion of YPK9. TAF1 encodes the largest transcrip-
tion factor TFIID subunit involved in RNA pol II transcription
initiation, promoter binding and G1/S progression (Walker et al.,
1997). Taf1p relocalizes to the cytosol in response to hypoxia,
whereas subsequent oxygen exposure restores the nuclear local-
ization (Dastidar et al., 2012). Also the expression of ATP13A2
in mammalian cells is upregulated in conditions of hypoxia (Xu
et al., 2012). In humans,TAF1 is associated with complex dystonia
(X-linked parkinsonism, unconfirmed genetic evidence) (Makino
et al., 2007) (reviewed in Lohmann and Klein, 2013; Klein, 2014).
This might suggest a putative link between ATP13A2 and TAF1
in humans. Human TAF1 possesses protein kinase, ubiquitin-
activating and -conjugating activities and histone acetyltrans-
ferase activities. These activities control transcription of genes
involved in the G1 progression in mammalian cells such as cyclin
D1 and cyclin A (Kloet et al., 2012).
OPI3 and YME1 are so far the only two positive genetic inter-
actors that have been identified. Thus, deletion of any of these
genes in combination with a deletion of YPK9 alleviates growth
effects caused by loss of either.OPI3 encodes the methylene-fatty-
acyl-phospholipid synthase, which catalyzes the last two steps in
phosphatidylcholine biosynthesis at the ER membrane in contact
zones with the plasma membrane (Tavassoli et al., 2013). YME1
encodes the catalytic subunit of the i-AAA protease complex
that is responsible for degradation of unfolded mitochondrial
proteins in the intermembrane space. Yme1p mediates Atg32p
processing, which is required for mitophagy (Wang et al., 2013).
It also contributes substantially to the proteolytic turnover of
phosphatidylserine decarboxylase-1 (PSD1) located at the mito-
chondrial inner membrane (Nebauer et al., 2007).
The link between YPK9 and themitochondria is further under-
scored by negative genetic interactions with six other genes
(ATP5, MDL2, MMM1, FMT1, GEP3, and OXR1) that encode
proteins related to mitochondrial function. Negative interactions
are defined as genes that upon deletion, in combination with a
YPK9 deletion, display aggravated growth effects as compared
to the loss of either individual gene. The six genes are related
Frontiers in Molecular Neuroscience www.frontiersin.org May 2014 | Volume 7 | Article 48 | 10
van Veen et al. Cellular role of ATP13A2 in Parkinson’s disease
FIGURE 5 | Genetic interactions of YPK9 in S. cerevisiae grouped
according to cellular localization and function. Summary of the known
genetic interactions of the yeast ATP13A2 ortholog YPK9. The data were
collected from the yeast genome database (http://yeastgenome.org, see
Supplemental Table 1) and were classified using BioGrid (http://thebiogrid.
org) according to organellar distribution and function.
to maintenance of mitochondrial homeostasis (ATP5, MDL2,
MMM1), mitochondrial biogenesis (FMT1, GEP3) and resistance
to oxidative damage (OXR1). Several interactors of YPK9 can thus
be related to mitochondrial function, which substantiates a link
between YPK9 and protection from oxidative stress.
The remaining majority of interactors related to YPK9 have
been identified in a genome-wide screen aimed at defining mech-
anisms by which YPK9 protects cells from Mn2+ toxicity in yeast
(Chesi et al., 2012). At physiological conditions, YPK9 genet-
ically interacts with essential genes involved in the cell cycle
(APC5, CDC28, CDC53, SFH1, POL3, CDC11 and CDC12), cel-
lular transport and vesicular trafficking (ALG1, GAB1, BET2
and MYO2) or RNA processing (DIM1). Cdc11p and Cdc12p
belong to the septin family, which includes highly conserved GTP-
binding proteins found in eukaryotes. Septins provide a scaffold
to support cell division, polarity and compartmentalization and
have been implicated in diverse neurodegenerative disorders in
humans, including in PD and α-synuclein mediated toxicity (Hall
and Russell, 2004). BET2 encodes the beta subunit of type II ger-
anylgeranyl transferase (Rossi et al., 1991) that is required for
vesicular transport between the ER and the Golgi (Newman et al.,
1990). Bet2p provides a membrane anchor to the Rab-like protein
Ypt1p, which like Ypk9p, protects yeast cells from α-synuclein
toxicity (Cooper et al., 2006).
Yeast genes involved in Mn2+ protection mainly belong to cat-
egories of vesicle-mediated transport, vacuolar organization and
chromatin remodeling (Chesi et al., 2012). YPK9 deletion mod-
ifies Mn2+ tolerance of a subset of these genes. Interactors that
increase Mn2+ sensitivity of YPK9 are implicated in vacuolar and
vesicle organization andmembrane fusion (such asVAM3,VAM6,
SWF1, and GLO3), whereas interactors that increase Mn2+ toler-
ance (such as SIF2, HMO1, LEO1, APQ12, and MOG1) seem to
be involved in chromatin organization, histone modification and
nuclear transport (Chesi et al., 2012). However, it is unclear why
none of the established Mn2+ or heavy metal transport systems
have been reported to be genetically linked to YPK9. This could
be because YPK9 is located upstream of established transport sys-
tems that take care of Mn2+ clearance. Ypk9p might for instance
be implicated in the regulation of vesicular transport routes that
control Mn2+ homeostasis. As Mn2+ ions are redox active Ypk9p
may also regulate the removal pathway of damaged mitochondria
via autophagy.
Taken together, the genetic interaction data from yeast suggest
a potential role for YPK9 in the cell cycle and vesicular trafficking
in combination with proper mitochondrial function.
ANIMAL MODELS OF ATP13A2
C. elegans
Caenorhabditis elegans contains three P5B genes, catp-5 to 7.
In contrast to the vacuolar/lysosomal localization of other P5B
ATPases, CATP-5 locates to the plasma membrane at the api-
cal side of intestinal cells (Heinick et al., 2010). catp-5 mutant
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strains are impaired in polyamine uptake (Heinick et al.,
2010). Polyamines are ubiquitous cellular components that affect
numerous biological processes such as cell cycle progression.
Polyamines interact with anionic binding sites of macromolecules
such as nucleic acids and phospholipids. catp-5 might either
encode a polyamine transporter or the gene might positively reg-
ulate polyamine uptake (Heinick et al., 2010). In mammalian
CHO cells, ATP13A2 overexpression leads to a two-fold higher
accumulation of the polyamine spermidine. It was shown that
the ATP-dependent spermidine uptake was increased in a lysoso-
mal and late endosomal fraction further supporting the notion
that the ATP13A2 protein mediates polyamine uptake (De La
Hera et al., 2013). The higher polyamine uptake rate might fur-
ther explain the increased cytotoxic effects of paraquat, a toxic
polyamine analogue that is an environmental risk factor for PD
(Pinto Fde et al., 2012).
CATP-6 locates depending on the tissue type to either cyto-
plasmic punctae likely corresponding to vesicles associated with
the lysosome or to the plasma membrane (Lambie et al., 2013).
catp-6, was identified in a RNAi screen for genes stabilizing syn-
thetic α-synuclein, representing a putative functional homologue
of ATP13A2 (Hamamichi et al., 2008). The catp-6 locus geneti-
cally interacts with gon-2 and gem-1 (Lambie et al., 2013). gon-2
encodes a TRPM cation channel protein that is required for
Mg2+ uptake, whereas gem-1 encodes for the SLC16A transporter,
which might be a putative monocarboxylate transporter. It was
suggested that the catp-6 gene product governs Mg2+ uptake
by regulating the trafficking of transporters or other regulatory
proteins to the plasma membrane (Lambie et al., 2013).
Mouse
The phenotype of a genetic knock-out mouse model of Atp13a2
was recently described (Schultheis et al., 2013). The insertion
site of the Neo gene in the genome of the Atp13a2−/− mice
would still allow the formation of a truncated and mutated N-
terminal Atp13a2 fragment consisting of the first 341 amino acids
of Atp13a2 followed by 168 unrelated amino acids. Although the
mutated transcript is clearly formed, no traces of the mutated
protein were detected, suggesting that it may either be unstable
or inefficiently translated (Schultheis et al., 2013).
As mentioned above, the Atp13a2−/− mice show α-synuclein
accumulation as occurs in PD and related synucleinopathies,
and accumulation of lipofuscin deposits, characteristic of NCL
(Schultheis et al., 2013). The α-synuclein aggregation occurred
predominantly in the hippocampus, but not in the cortex or
cerebellum. Also the expression of some genes involved in PD is
altered between the striatum and substantia nigra in Atp13a2−/−
vs. Atp13a2+/+ mice (Schultheis et al., 2013).
Twenty to twenty nine months old Atp13a2−/− mice perform
more poorly on several sensorimotor tests. More specifically, the
aged Atp13a2−/− mice display impaired aspects of motor learn-
ing. The gait analysis revealed a shortened stride length. Also
reduced hindlimb stepping, impairments in fine motor skills and
orofacial movements involved in nest building were reported
(Schultheis et al., 2013). These deficits are similar to those
observed in other genetic mousemodels of PD and ataxia and also
resemble aspects of motor dysfunction observed in KRS, NCL,
and PD (Schultheis et al., 2013). Cognitive function and emo-
tional reactivity were also changed in Atp13a2−/− mice. Mutant
mice demonstrated greater exploratory behavior without changes
in general locomotor activity or anxiety. Because the behavioral
phenotype was not detectable until old age, some compensatory
mechanisms might take place, which might be related to other
members of the P5-ATPase family. But so far, no evidence was
found for a compensatory upregulation of other P5-type ATPases
(Schultheis et al., 2013).
Zebra fish
In contrast, knocking out ATP13A2 in the zebra fish results in
severe retardation already at the embryonic stage of development
(Lopes da Fonseca et al., 2013). As the mouse genome con-
tains four P5B genes (Atp13a2-5), while the zebra fish only one
(ATP13A2), the late-onset mouse phenotype associated with loss
of ATP13A2 would suggest that some of the P5B homologues in
mice may be functionally redundant, possibly compensating for
each other’s loss (Schultheis et al., 2013). Further studies will be
required to shed light on the possible redundancy of P5B function
and whether compensatory effects from other P5 alleles can take
place.
CELLULAR ROLES OF HUMAN ATP13A2
ATP13A2 EXPRESSION PROFILE
ATP13A2 is mapped to the PARK9 PD susceptibility locus on
chromosome 1p36. ATP13A2 is predominantly expressed in the
brain, particularly in the dopaminergic neurons of the substan-
tia nigra (Ramirez et al., 2006). Studies in mouse have shown
that Atp13a1 (P5A) and Atp13a2 (P5B) are broadly expressed in
many tissues with the highest expression of Atp13a2 observed in
the brain. Atp13a4 and Atp13a5 (both P5B) are only expressed
in brain and stomach while Atp13a3 (P5B) has a wider expres-
sion pattern that includes brain and other internal organs like
colon, kidney and liver (Schultheis et al., 2004). It thus seems that
all P5-type ATPase isoforms are expressed in the brain although
individual members express at different levels during various
developmental stages. Expression of Atp13a2 peaks during neu-
rogenesis while Atp13a5 peaks at the adult stage (Weingarten
et al., 2012). These observations are in line with a significant,
yet undescribed role for P5B ATPases in brain development and
function.
At least three ATP13A2 splice variants are reported (Ugolino
et al., 2011). Variant 1 is the longest and counts 1180 amino acids.
Variant 2 contains a five amino acid in-frame deletion in the N-
terminus (1175 amino acids), whereas variant 3 is 1158 amino
acids long and appears to be an anomalous protein. Here, the last
two TM helices are replaced by an unusual sequence stretch and
variant 3 also lacks an important part of the connection of the
TM region with the cytosolic domains. Based on comparison with
other P-type ATPases these alterations will probably have a signif-
icant impact on enzymatic activity. Variant 3 is retained in the ER
and is rapidly degraded, questioning whether it serves a cellular
role (Ugolino et al., 2011).
The promoter region of the human ATP13A2 gene contains
hypoxia response elements, which can bind to the transcription
factor hypoxia inducible factor 1a (HIF-1a). Hypoxic conditions
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up-regulate transcription of the ATP13A2 gene in both HEK293
and dopaminergic MN9D cells (Xu et al., 2012). Also Mn2+ and
Zn2+ elevate ATP13A2 expression in several cell lines (see further
details below) (Tan et al., 2011; Tsunemi and Krainc, 2014).
INTRACELLULAR LOCALIZATION OF ATP13A2
The general accepted view is that ATP13A2 is targeted to acidic
compartments, i.e. the late endosomes and lysosomes, because of
a co-localization with LAMP1/2a, Rab7, and Lysotracker. Also the
loss of ATP13A2 leads to lysosomal dysfunction and an increase
in the size and number of the lysosomes (Dehay et al., 2012b;
Usenovic et al., 2012a). Originally, it was suggested that ATP13A2
is localized to late endosomes/lysosomes based on overexpression
studies of tagged ATP13A2 (Ramirez et al., 2006). However, this
view was recently challenged (Kong et al., 2014). In both differ-
entiated SHSY5Y cells and rat primary neurons, the endogenous
ATP13A2 associates closely together with LC3, a marker of the
autophagosomes. More specifically, the authors concluded that
the endogenous ATP13A2 occupies the outer limiting membrane
of multivesicular bodies (MVBs), a morphologically distinctive
late endosome compartment. MVBs undergo dynamic rearrange-
ments and sorting of lipids and proteins via inward budding of
the membrane generating multiple intra-luminal vesicles (ILVs).
By fusing with the plasma membrane, MVBs can release the ILVs
in the extracellular space as exosomes. MVBs can also fuse with
autophagosomes from autophagy pathways producing hybrid
structures referred to as amphisomes, which then can fuse with
lysosomes for cargo degradation. ATP13A2 is also observed in the
outer membrane of amphisomes (Kong et al., 2014).
ATP13A2 IS INVOLVED IN AUTOPHAGY AND MITOCHONDRIAL
CLEARANCE
Mitochondrial dysfunction is tightly linked to the pathogene-
sis of PD (Auluck et al., 2010; Jin and Youle, 2012; Gautier
et al., 2014). Strong support comes from the observations that
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), a potent
mitochondrial complex I inhibitor, triggers a PD-like syndrome
(Burns et al., 1983; Langston and Ballard, 1983). Several PD-
associated genes, namely parkin, PINK1 and DJ-1 play a role in
mitochondrial dynamics and clearance strengthening the con-
cept that mitochondrial dysfunction and the production of ROS
are consistent features of PD (Auluck et al., 2010; Jin and Youle,
2012). Thus, clearance of dysfunctional or damaged mitochon-
dria and misfolded proteins is essential for neuronal fitness and
survival (Jin and Youle, 2012; Gautier et al., 2014) and the
lysosome is a vital organelle for this quality control (Jin and
Youle, 2012; Tofaris, 2012; Dehay et al., 2013). Organelles, cyto-
plasmic material and protein aggregates are delivered to the
lysosome via various autophagy pathways. Macroautophagy (or
just autophagy) involves the formation of double-layered mem-
brane autophagosomes, which encapsulate cytoplasmic materials
for delivery to the lysosomes for degradation. Mitochondria are
removed through a specific autophagy pathway called mitophagy
(Jin and Youle, 2012). Soluble proteins can also be selectively
degraded in the lysosome through uptake by the lysosomal
receptor LAMP2a, via a process known as chaperone-mediated
autophagy (CMA) (Mak et al., 2010). Micro-autophagy involves
the direct engulfment of cytoplasmic material by invagination
of the late endosomal/lysosomal membrane. Whereas the func-
tion of micro-autophagy in mammalian cells is unknown, both
macro-autophagy and CMA are key processes in neurodegenera-
tion and α-synuclein removal (Webb et al., 2003; Mak et al., 2010)
(reviewed in Xilouri and Stefanis, 2011).
Studies in KRS patient-derived fibroblasts and ATP13A2-
deficient cell lines have revealed that mutations of ATP13A2
or knockdown of the gene transcript lead to several lysosomal
alterations. First the number and size of lysosomes is increased
(Usenovic et al., 2012a). Also lysosomal dysfunction is reported
involving impaired lysosomal acidification, decreased proteolytic
processing of lysosomal enzymes, reduced degradation of lyso-
somal substrates (e.g., α-synuclein) and impaired lysosomal-
mediated clearance of autophagosomes (Dehay et al., 2012b;
Usenovic et al., 2012a; Tsunemi and Krainc, 2014).
In parallel, a strong link between ATP13A2 and mitochondrial
dysfunction is emerging. Loss of ATP13A2 function impairs mito-
chondrial maintenance and leads to oxidative stress. ATP13A2
expression protects mammalian cells toward mitochondrial and
oxidative stress (Covy et al., 2012). In fibroblasts of patients with
non-functional ATP13A2 ATP production rates are decreased.
Also a higher frequency of mitochondrial DNA lesions, increased
oxygen consumption rates and increased fragmentation of the
mitochondrial network have been observed (Grunewald et al.,
2012).
A role for ATP13A2 in autophagy and mitochondrial clear-
ance has been suggested, but mechanistic details are lacking
(Grunewald et al., 2012; Gusdon et al., 2012; Park et al.,
2014). ATP13A2 regulates mitochondrial bioenergetics through
macroautophagy. ATP13A2 knockdown reduces the autophagic
flux in SHSY5Y cells (Gusdon et al., 2012) and lysosomal-
mediated clearance of autophagosomes was impaired in patient-
derived ATP13A2−/− fibroblasts (Dehay et al., 2012b) and in
ATP13A2 knockdown neurons (Usenovic et al., 2012a). Several
physical interactors of ATP13A2 are involved in mitophagy
whereas others are involved in protein quality, protein sort-
ing, vesicular transport and membrane fusion (Usenovic et al.,
2012b). Evidence from genetic interaction studies in yeast also
provides a link between YPK9 and mitochondrial clearance (see
above).
The fact that ATP13A2 expression is upregulated under oxida-
tive stress (Xu et al., 2012) seems to indicate that ATP13A2
is particularly important in conditions of oxidative stress, for
instance arising frommitochondrial dysfunction. Defective mito-
chondrial clearance may also account for the increased sensitivity
toward Zn2+ toxicity in ATP13A2−/− cells (Park et al., 2014).
Indeed, Zn2+ induces mitochondrial ROS production, which
results in mitochondrial dysfunction and fragmentation (Park
et al., 2014). Importantly, treatment with an antioxidant com-
pletely abolishes Zn2+-induced cell death in ATP13A2−/− cells
(Park et al., 2014). The link between Zn2+ and mitochondrial
stress is further emphasized by the observation that Zn2+ poten-
tiates, whereas Zn2+ chelation protects against MPTP-induced
PD (Sheline et al., 2013). Along the same lines, loss of ATP13A2
and impaired mitochondrial clearance may explain the observed
intolerance toward Mn2+ (Gitler et al., 2009; Schmidt et al.,
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2009) and paraquat (Pinto Fde et al., 2012). Since polyamines can
function as ROS scavengers, the increased uptake of polyamines
(De La Hera et al., 2013) may protect ATP13A2−/− cells toward
oxidative stress, although high levels of polyamines are also toxic.
Together, these observations suggest that ATP13A2 controls
mitochondrial maintenance, which would lend further support to
converging lysosomal and mitochondrial pathways in PD patho-
genesis (Jin and Youle, 2012; Tofaris, 2012; Dehay et al., 2013).
By controlling the autophagy-lysosomal activity ATP13A2 may
serve an essential function by removing damaged or dysfunctional
proteins and organelles.
ATP13A2 IS INVOLVED IN VESICULAR TRANSPORT
The long list of putative physical interactors (Usenovic et al.,
2012b) points into the direction of ATP13A2 as a scaffolding pro-
tein in the regulation of vesicular processes. Like other P-type
ATPases, such as the Na+/K+-ATPase (Xie and Xie, 2005) and
the SERCA2 Ca2+-ATPase (Vangheluwe et al., 2005), ATP13A2
might be acting as a scaffold and exert a transporting function
at the same time. Regulation of vesicular processes may include
de novo vesicle formation, vesicular transport, vesicular sorting
mechanisms and vesicle fusion. E.g. ATP13A2 directly interacts
with several components of the SNARE complex that is involved
in vesicle docking and fusion (Usenovic et al., 2012b). A function
in vesicular transport can be easily reconciled with the estab-
lished roles of ATP13A2 in mitochondrial clearance (Gusdon
et al., 2012; Park et al., 2014) and α-synuclein removal (Gitler
et al., 2009; Kong et al., 2014), which depend on autophagy path-
ways. In addition, ATP13A2 controls vesicle-dependent Zn2+ and
α-synuclein removal mechanisms through exosomes, which are
ILVs formed in the MVBs that fuse with the plasma membrane
(Kong et al., 2014). Genetic evidence in yeast also provides a link
between YPK9 and vesicular transport (see above).
THE CONNECTION BETWEEN ATP13A2 AND α-SYNUCLEIN
ATP13A2 protects cells toward α-synuclein toxicity. This has been
observed in several model systems including yeast, C. elegans and
mammalian cells (Gitler et al., 2009). Like α-synuclein, ATP13A2
might be implicated in vesicle trafficking and mitochondrial dys-
function. Several hypotheses may explain the protective effect of
ATP13A2.
(a) By regulating lysosomal functions ATP13A2 might control
lysosomal α-synuclein degradation and prevent the build-up
of α-synuclein aggregates (Dehay et al., 2012b; Usenovic et al.,
2012a; Tsunemi and Krainc, 2014).
(b) Alternatively, ATP13A2 may control the delivery of α-
synuclein to the lysosomes by regulating different autophagy
pathways such as macro-autophagy (Dehay et al., 2012b;
Usenovic et al., 2012a) and chaperone-mediated autophagy,
two autophagic routes that control α-synuclein turnover
(Webb et al., 2003; Mak et al., 2010).
(c) α-synuclein may prevent the membrane fusion of the mito-
chondria resulting in increased mitochondrial fragmentation
(Kamp et al., 2010). α-synuclein also impairs mitochon-
drial function (Auluck et al., 2010). The protective effect
of ATP13A2 toward α-synuclein toxicity might therefore be
related to the positive effect of ATP13A2 on mitochondrial
appearance (Grunewald et al., 2012; Gusdon et al., 2012; Park
et al., 2014), which might compensate excessive mitochon-
drial fragmentation. One can speculate that via promotion of
mitochondrial clearance, ATP13A2 might provide protection
toward α-synuclein-induced mitochondrial fragmentation.
(d) ATP13A2 promotes the removal of α-synuclein out of the cell
via exosomes reducing the α-synuclein stress in cells (Kong
et al., 2014).
(e) As α-synuclein interacts with membranes and the amount of
α-synuclein interaction with the membrane seems to corre-
late with the degree of toxicity (Auluck et al., 2010; Kuwahara
et al., 2012), it is a tempting hypothesis that ATP13A2 might
affect α-synuclein membrane interactions.
ATP13A2 CONTROLS CELLULAR ION HOMEOSTASIS
ATP13A2 causes protection toward several heavy metals (Gitler
et al., 2009; Schmidt et al., 2009; Kong et al., 2014) and in KRS
patients iron deposits in the brain are observed (Bruggemann
et al., 2010; Schneider et al., 2010). The prevailing hypothesis is
therefore that ATP13A2 is a lysosomal cation pump (Gitler et al.,
2009). This hypothesis is furthermore based on sequence similar-
ity with other P-type ATPases (Ramirez et al., 2006), among which
most transport cations, e.g., to generate vital electrochemical ion
gradients, to relocalize essential elements or dispose toxic metal
ions.
WHAT IS THE TRANSPORTED LIGAND—IF ANY—OF
ATP13A2?
Although P5B ATPases have essentially all sequence requirements
to act as transporters, their ligands so far remain unidentified.
ATP13A2 may regulate lysosomal function by transporting ions
(Gitler et al., 2009) or an essential co-factor required for lyso-
somal enzyme activity (Covy et al., 2012). ATP13A2 might also
take up metal ions in lysosomes or MVBs/exosomes to remove
excess ions (Kong et al., 2014). The possibility that ATP13A2
works closely together with the V-type ATPases to pump pro-
tons to contribute to the low pH in the late endosome/lysosome
can also not be excluded (Dehay et al., 2012b). In this section
we will critically review the prevalent concept that ATP13A2 is
a cation transporter by comparing sequence characteristics of
ATP13A2 with better described P-type ion pumps and discussing
the available physiological and biochemical evidence for trans-
port of proposed ligands. Finally, we discuss the possibility that
ATP13A2 might pump organic ions, such as lipids or peptides
from one membrane leaflet to the other.
CATION(S) POSSIBLY TRANSPORTED BY ATP13A2
ATP13A2 has been linked to Mn2+, Zn2+, Mg2+, and H+ home-
ostasis suggesting that ATP13A2 might be implicated in the
transport of these cations.
Is ATP13A2 a Mn2+ transporter?
ATP13A2 was first suggested to be a lysosomal Mn2+ transporter
(Gitler et al., 2009). Mn2+ is a biologically relevant metal that
functions as a cofactor of many enzymes, such as carboxylases
and phosphatases in the cytosol, sugar transferases and sulfatases
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in the Golgi and the mitochondrial superoxide dismutase SOD2
(Vangheluwe et al., 2009; Tuschl et al., 2013). Little is known
about Mn2+ requirements in lysosomes or MVBs, but Mn2+
uptake in the MVBs and lysosome could constitute a Mn2+
detoxification pathway to remove excessive Mn2+. This would
prevent Mn2+ toxicity, which evokes extrapyramidal syndromes
resembling PD and dystonia (Vangheluwe et al., 2009; Tuschl
et al., 2013). Mn2+-induced cell death involves oxidative stress,
interference with Ca2+ and iron homeostasis, DNA damage and
mitochondrial dysfunction (Tan et al., 2011). It is thus clear that
Mn2+ levels need to be properly controlled, but the responsible
pathways remain incompletely understood.
A role of ATP13A2 in Mn2+ homeostasis and Mn2+ tox-
icity has been proposed based on the following observations.
Loss of YPK9 in yeast leads to an increased sensitivity toward
Mn2+ (Gitler et al., 2009; Schmidt et al., 2009), whereas
mammalian cells (HEK293, Neuro2a and NLF neuroblastoma
cells) that overexpress ATP13A2 showed resistance to MnCl2-
induced cytotoxicity (Tan et al., 2011; Covy et al., 2012). Atomic
absorption spectrophotometry further revealed that HEK293 cells
overexpressing ATP13A2 accumulate less Mn2+ when cells were
pre-exposed to MnCl2. Also the endogenous ATP13A2 expres-
sion levels increase when HEK293 cells are exposed toMnCl2(Tan
et al., 2011). Thus, ATP13A2 regulates and is controlled by
the intracellular Mn2+-concentration providing a strong link
between ATP13A2 andMn2+ homeostasis. Although these obser-
vations indicate that ATP13A2 is implicated in the removal path-
way for Mn2+, the available evidence that ATP13A2 would be a
Mn2+ transporter remains circumstantial since no direct Mn2+
transport or lysosomal Mn2+ uptake has been demonstrated.
For instance, instead of possibly transporting Mn2+ directly,
ATP13A2 might influence other Mn2+ removal pathways which
can depend on vesicular transport and/or other Mn2+ carri-
ers. It is clear that efficient Mn2+ resistance in yeast depends
on all steps in the secretory pathway involving proteins of
vesicle-mediated transport, vacuolar organization and chromatin
remodeling (Chesi et al., 2012). This suggests that Mn2+ removal
may occur mainly via vesicular transport routes. In the brain,
Mn2+ detoxification also depends on several members of the
solute carrier (SLC) family including the proton coupled trans-
porters SLC11A2/DMT1/NRAMP2 and SLC40A1/ferroportin,
the putative Zn2+/Mn2+ transporter SLC30A10/ZnT10 and
SLC39A14/ZIP14 (DeWitt et al., 2013; Tuschl et al., 2013). These
proteins are involved in Mn2+ transport and typically carry sev-
eral metal species. SLC members are involved in the transport of
several divalent metal cations, such as Zn2+, Mn2+, Fe2+, Ni2+,
Cu2+, Co2+, and Cd2+. This is also the case for the transfer-
rin receptor (TfR) carrying Fe2+ and trivalent Mn3+ (DeWitt
et al., 2013) and for the Secretory Pathway Ca2+/Mn2+-transport
ATPase SPCA1/PMR1 (Vangheluwe et al., 2009). The relative
importance of all these Mn2+ transporters or removal pathways
in the brain or how ATP13A2 affects these pathways remains to
be determined.
Several Mn2+ transport routes were studied in neuronal cells.
Mn2+ is sequestered into the Golgi/secretory pathway compart-
ments by SPCA1/PMR1, which also belongs to the P-type ATPase
family (P2-type) (Vangheluwe et al., 2009). So far, the two SPCA
isoforms SPCA1 (ubiquitous) and SPCA2 (secretory cells) are the
only known P-type ATPases in animals that transport Mn2+ in
intracellular stores with a high affinity. As such, SPCA1 might be
implicated in the removal of toxic Mn2+ from neurons through
the secretory pathway (Vangheluwe et al., 2009). However, SPCA
expression levels decrease withMn2+-exposure and SPCA activity
is inhibited by high concentrations ofMn2+, suggesting that other
Mn2+-removal mechanisms may prevail in neurons (Sepulveda
et al., 2012).
The ubiquitous ZIP14 is present in the plasma membrane
and promotes Mn2+ uptake in SHSY5Y neuroblastoma cells.
Conversely, SLC30A10 controls Mn2+ secretion in SHSY5Y cells,
which is thought to be a Mn2+ transporter (Quadri et al., 2012).
Mutations in SLC30A10 cause extreme neurotoxic accumulation
of Mn2+ in liver and brain triggering dystonia and parkinsonism
(Quadri et al., 2012). The subcellular localization of SLC30A10
matches with different compartments, such as the Golgi system,
endosomes, and the plasma membrane (Quadri et al., 2012).
The human SLC30A10 complements defective Mn2+ uptake in
yeast cells lacking the Ca2+/Mn2+ ATPase PMR1 (Tuschl et al.,
2012) and the endogenous SLC30A10 expression increases with
Mn2+ exposure in HepG2 hepatocellular carcinoma cells. These
observations provide a strong link between SLC30A10 and main-
tainingMn2+ homeostasis. Finally, neurons also take up Fe2+ and
trivalent Mn3+ via DMT1 and TfR (DeWitt et al., 2013).
Is ATP13A2 a Zn 2+ transporter?
Besides Mn2+, Ypk9p protects yeast against other heavy met-
als, including Zn2+, Cd2+, Ni2+, and Se2+ (Gitler et al., 2009;
Schmidt et al., 2009; Kong et al., 2014). In mammalian cell sys-
tems, a link between ATP13A2 and Mn2+, Ca2+, Cd2+, Zn2+,
or Ni2+ homeostasis has been reported. A protective effect of
ATP13A2 overexpression toward Ni2+ and Mn2+ in mammalian
NLF cells was described (Covy et al., 2012), whereas the knock-
down of ATP13A2 increases the sensitivity of SHSY5Y cells
toward Zn2+, but strangely not Mn2+. This challenges the view
that ATP13A2 would be a Mn2+ transporter. Peptide fragments
of ATP13A2 bind Mn2+, Zn2+, and copper (Remelli et al., 2013).
ATP13A2 also regulates basal and Cd2+-induced intracellular
Ca2+ levels in neurons (Ramonet et al., 2012).
Several recent studies underscored a strong link between
ATP13A2 and Zn2+ homeostasis (Kong et al., 2014; Park et al.,
2014; Tsunemi and Krainc, 2014). Thus, Zn2+ is another strong
candidate ligand for ATP13A2-mediated transport. Neurons are
sensitive to both Zn2+ deficiency and excess (Sensi et al., 2009)
and Zn2+ levels are increased in PD (Hozumi et al., 2011).
Fibroblasts carrying homozygous or compound heterozygous
ATP13A2 disease mutations and also patient-derived olfactory
neurospheres (hONs), mouse primary embryonic cortical neu-
rons and SHSY5Y cells with ATP13A2 knock down are highly sen-
sitive to Zn2+ exposure, whereas sensitivity to Mn2+ is less pro-
nounced (Kong et al., 2014; Park et al., 2014; Tsunemi and Krainc,
2014). In addition, the expression of endogenous ATP13A2 in
primary neurons was elevated in the presence of Zn2+ (Tsunemi
and Krainc, 2014). In conditions of Zn2+ overload, the acidic or
LC3-positive vesicles of ATP13A2−/− cells accumulate less Zn2+
(Park et al., 2014; Tsunemi and Krainc, 2014). Conversely, via
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X-ray fluorescence microscopy total intracellular Zn2+ levels were
estimated to be 60% higher in ATP13A2−/− hONs than in con-
trol cells (Kong et al., 2014). This would suggest that ATP13A2
contributes to Zn2+ efflux from the cell.
Whether ATP13A2 pumps Zn2+ directly or rather affects other
Zn2+ transporters or vesicular transport remains to be clarified.
In the hONs, the majority of known secondary Zn2+ transporters
were upregulated in ATP13A2−/− cells, pointing to a severe Zn2+
dyshomeostasis. These include 9 members of the SLC30 family
of Zn2+ transporters (ZnTs) that mediate Zn2+ efflux and 14
members of the SLC39 family of ZRT/IRT-related proteins (Zn2+
importing proteins, ZIP) that facilitate influx of Zn2+ (Park et al.,
2014). It is unclear how much of the altered expression pattern of
these Zn2+ transporters explains the mislocalization of Zn2+ in
ATP13A2 deficient cells.
Nevertheless, the result of impaired ATP13A2 activity is a rise
in cytosolic Zn2+ concentrations. Zn2+ dyshomeostasis has been
associated with a variety of neurological disorders (Sensi et al.,
2009). This affects multiple cellular functions including the mito-
chondria (Park et al., 2014) and lysosomes (Tsunemi and Krainc,
2014), making it difficult to assess the underlying mechanism
of ATP13A2-mediated Zn2+ protection. Zn2+ induces lysosomal
dysfunction, which negatively impacts on lysosomal pH, lysoso-
mal proteolysis and accumulation of α-synuclein (Tsunemi and
Krainc, 2014). Loss of ATP13A2 also leads to lysosomal dysfunc-
tion, which potentiates the Zn2+-related effects (Dehay et al.,
2012b; Tsunemi and Krainc, 2014).
Zn2+ is not involved in redox reactions and therefore does not
generate oxidative stress by itself. However, excessive mitochon-
drial Zn2+ uptake in conditions of high Zn2+ exposure inhibits
several enzymes and complexes of the mitochondria leading to
the production of ROS. This imposes oxidative stress, which can
induce cell death (Park et al., 2014). As mentioned above, the
loss of ATP13A2 is associated with mitochondrial dysfunction,
which is related to impaired mitochondrial clearance, presum-
ably due to insufficient lysosomal degradation (Grunewald et al.,
2012; Gusdon et al., 2012; Ramonet et al., 2012). The improper
cytosolic removal of Zn2+ in ATP13A2−/− cells might further
impose mitochondrial stress, triggering severe ROS production
(Park et al., 2014). Moreover, an increased accumulation of fail-
ing mitochondria in ATP13A2−/− cells in conditions of Zn2+
exposure may contribute to the increased sensitivity of Zn2+. The
extensive mitochondrial dysfunction and fragmentation may lead
to ATP depletion and/or ROS production resulting in cellular
degeneration. Importantly, treatment with an antioxidant com-
pletely abolishes Zn2+-induced cell death in ATP13A2−/− cells,
indicating that the ROS production during Zn2+-induced mito-
chondrial failure largely accounts for the toxic effects of Zn2+
(Park et al., 2014).
In conclusion, it appears that the Zn2+ phenotype of
ATP13A2−/− cells can largely be explained without imposing that
ATP13A2 is a Zn2+ transporter.
Is ATP13A2 a Mg2+ transporter?
The ATP13A2 homologue Kil2 in Dicytostelium discoideum, a
phagocytic bacterial predator, is required for Mg2+-dependent
killing of ingested Klebsiella (Lelong et al., 2011). Also the
ATP13A2 homologue CATP-6 in C. elegans has been implicated
in Mg2+ uptake (Lambie et al., 2013). In a purified system, the
ATPase activity of the P5A ATPase Spf1p in S. cerevisiae is stim-
ulated by Mg2+ ions (Cronin et al., 2002). These observations
might indicate that Mg2+ plays a role in both P5A and P5B
ATPases. However, all P-type ATPases require Mg2+ for proper
ATP coordination and phosphorylation of the conserved Asp in
the P-domain (Moller et al., 2010). So for any P-type ATPase it
is difficult to discriminate between transport or non-transport
related effects of Mg2+ on the ATP-hydrolytic activity.
Is ATP13A2 a H+ transporter?
ATP13A2 is present in acidic compartments. Because loss of
ATP13A2 leads to an elevated lysosomal pH, ATP13A2 might be
involved in organellar acidification (Dehay et al., 2012b; Tsunemi
and Krainc, 2014). However, whether the lysosome would require
additional H+ pumps is questionable, as lysosome acidifica-
tion primarily depends on the activity of V-type ATPases, which
are highly efficient and abundant lysosomal H+ pumps. V-type
ATPases also work together with Cl− channels for generating the
steep H+ gradient in the lysosome (Marshansky and Futai, 2008).
Can the ATP13A2 TM sequence support ion transport?
Establishing conclusively that ATP13A2 is a cation transporter
will depend on a biochemical characterization of the purified
pumps reconstituted in lipid vesicles that allow for measure-
ments of transport. So far, we can only question whether the
ATP13A2 protein supports Zn2+, Mn2+, Mg2+, or H+ transport.
As explained before, the M4 region in P-type ATPases is criti-
cally involved in substrate coordination and specific M4 sequence
motifs correlate well with substrate specificity. We first compared
the sequence of ATP13A2 with SPCA, an established P-typeMn2+
transport ATPase (Figure 4). M4 of ATP13A2 (PPALP) strikingly
differs from the SPCA M4 region (PEGLP). The Glu residue that
coordinates Mn2+ and serves as a gating residue is absent in
ATP13A2 and is replaced by a hydrophobic residue that is diffi-
cult to reconcile with ion binding. However, ion-coordination in
SPCA not only depends on M4, but also involves oxygen atoms
of the peptide backbone and polar residues positioned on M5
and M6 (Vangheluwe et al., 2009). In ATP13A2, at least one con-
served negatively charged residue is found in M6 and conserved
polar residues are found on M4, M5 and M6, which in theory
could support ion coordination (Figure 4) (Sorensen et al., 2010).
Notably, critically conserved Asp residues in the M6 segment
of the P3 plasma membrane H+-ATPase (Buch-Pedersen et al.,
2009) and the P2 Ca2+-ATPases (Toyoshima et al., 2000) play a
role in respectively H+ coordination and Ca2+ coordination.
Coordination of Zn2+ typically involves His and/or Cys
residues (Simonson and Calimet, 2002). Also in the P-type
ATPase heavy metal transporters, conserved Cys residues are
found in the M4 region (a CPC motif in the CopA copper trans-
porter) (Gourdon et al., 2011). No obvious conserved His, Cys
or even a Met are found in the TM region of ATP13A2, ques-
tioning whether coordination of Zn2+ may occur. However, a
striking similarity is observed between ATP13A2 and the P1B
heavy metal P-type ATPases, which both have extra N-terminal
helices in common (Sorensen et al., 2010; Gourdon et al., 2011).
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In the CopA copper transporter, the N-terminal platform recruits
metal-chaperones for copper delivery (Gourdon et al., 2011).
Whether metal chaperones would bind ATP13A2 remains to be
tested. Several putative ATP13A2 interactors were identified with
a split-ubiquitin yeast two hybrid screening (Usenovic et al.,
2012b) and several genetic interactions for YPK9 were identified
in yeast (Chesi et al., 2012), but no obvious metal chaperones or
proteins involved in metal transport were found.
In conclusion, at least some residues in the M-region of
ATP13A2might support ion binding, but the overall composition
significantly differs from other P-type Mn2+ and Zn2+ trans-
porters. So until strong biochemical evidence becomes available,
we may need to consider other possibilities.
IS ATP13A2 A LATE ENDOSOMAL/LYSOSOMAL FLIPPASE?
Among the P-type ATPases the 14 members of the P4 ATPases
transport other ligands than inorganic cations. Members of this
subfamily flip phospholipids from one membrane leaflet to the
other. Because P5 ATPases phylogenetically are more related to
P4 ATPases than to any other P-type ATPase subfamily (Figure 1)
(Axelsen and Palmgren, 1998), it may be interesting to consider
the possibility that P5 ATPases likewise might be involved in lipid
or organic ion transport. The structural requirements of P4-type
flippases are only just emerging and candidate residues have been
identified that are important for lipid transport (Coleman et al.,
2012; Baldridge and Graham, 2013; Baldridge et al., 2013). An
Ile residue in the conserved P4 sequence motif on M4 (PISL)
appears important for the binding and translocation of the phos-
pholipid and shows functional analogy to a conserved Glu in M4
of P2-type ATPases that in these pumps serve as a gating residue
(Vestergaard et al., 2014). At this point it remains hard to say
whether P5B-type ATPases fulfill the sequence requirements of a
typical flippase. Remarkably, a Pro in the M4 motif of the P5 is
found at the position of the conserved Glu in P2 and Ile in P4.
Amongst other possible hypotheses, we should consider the
possibility that ATP13A2 might be a flippase that transports a
lipid or another organic molecule from one membrane leaflet to
the other. Such an activity might in turn control vesicular depen-
dent processes that regulate ion homeostasis, exosome formation,
mitophagy/autophagy and α-synuclein clearance.
As a putative (lipid) flippase, ATP13A2 might alter membrane
curvature, alter lipid dynamics, organize lipid microdomains
or expose/remove important signaling molecules at one or the
other membrane leaflet (Graham, 2004; Palmgren and Nissen,
2011), which might for instance regulate α-synuclein membrane
interactions. Moreover, ATP13A2 is implicated in mitochondrial
clearance and exosome formation at the site of the late endo-
some, MVB and lysosome. A putative (lipid) flippase might here
be strategically important as these organelles undergo continu-
ous vesicle forming and vesicular fusion events to deliver, sort
or remove cargo. This might require a tight regulation of mem-
brane dynamics. At the end station for autophagsome delivery,
ATP13A2 might control the fusion process of the autophago-
somes. ATP13A2might for instance compose a fusion-compatible
lipid microdomain or expose important signaling molecules
required for fusion. Alternatively, changes in the lysosomal lipid
distribution may regulate autophagy pathways, which are known
to be sensitive to changes in the lipid environment (Ferguson
et al., 2009; Rodriguez-Navarro et al., 2012). ATP13A2 might
regulate micro-autophagy, a process depending on membrane
invagination to take up cargo for degradation. It might also be
involved in the formation of intraluminal vesicles of the MVBs
which impacts on α-synuclein removal (Kong et al., 2014).
CONCLUSION
Although the cell biological context in which ATP13A2 is involved
is gradually emerging, studying the molecular function and sub-
strate specificity of ATP13A2 using biochemical methods and iso-
lated systems will be required to unravel the substrate specificity
and transport properties of ATP13A2. Understanding ATP13A2
at the molecular level will reveal its link to KRS, NCL, dystonia,
and PD. This might open new therapeutic possibilities to treat this
spectrum of disorders.
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